Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 4,560 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: assessment only control Clear all

Conditions: Dental Caries
Interventions: C16G2 Strip, Placebo Strip; Drug · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 3
States / cities: Kalispell, Montana • Bedford, Texas • Irving, Texas

Conditions: Systemic Lupus Erythematosus
Interventions: Mycophenolate Mofetil, Placebo for Mycophenolate Mofetil, Voclosporin, Placebo for Voclosporin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 6 more

Conditions: Chronic Plaque-type Psoriasis
Interventions: CJM112, Secukinumab, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 18
States / cities: Anniston, Alabama • Anaheim, California • Encino, California + 14 more

Conditions: Fecal Incontinence, Neurogenic Bowel
Interventions: Dose Response - NS and USP Glycerin - First Intervention, Effectiveness - NS and USP Glycerin - Second Intervention; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 3 Years to 12 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions: V114, Prevnar 13™; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years and older
Enrollment: 2,340 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 30
States / cities: Chandler, Arizona • Mesa, Arizona • Fountain Valley, California + 26 more

Conditions: HIV Infections
Interventions: VH4004280, VH4011499, VH4004280 Matching Placebo, VH4011499 Matching Placebo, Antiretroviral therapy; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Bakersfield, California • DeLand, Florida • Newark, New Jersey

Conditions: CVA, Gait, Hemiplegic
Interventions: EksoGT™, Ekso Bionics, Berkley, CA, USA, Standard of Care, No Intervention; Device · Other
Lead sponsor: Kessler Foundation; Other
Eligibility: 21 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Aging, Fall Injury
Interventions: Medication Action Plan and Patient Empowerment (MAP-PE ); Behavioral
Lead sponsor: University of Iowa; Other
Eligibility: 60 Years to 110 Years
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Clive, Iowa

Conditions: Spinal Cord Injuries (SCI)
Interventions: No Stimulation, Conventional tSCS, Spatiotemporal tSCS; Other · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 16 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy
Interventions: PRT064445, Placebo; Biological · Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Psoriasis
Interventions: DFD06; Drug
Lead sponsor: Primus Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 9
States / cities: Madera, California • Santa Ana, California • Hialeah, Florida + 5 more

Conditions: HPV Vaccination, Uptake Vaccination, Series Completion
Interventions: PREVENT; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Lyme Disease
Interventions: VLA15, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 7 Years and older
Enrollment: 1,712 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 19
States / cities: Bangor, Maine • Worcester, Massachusetts • Flemington, New Jersey + 13 more

Conditions: Depressive Disorder, Major
Interventions: Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 84
States / cities: Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 65 more

Conditions: Ketamine-Induced Brain Activity Changes, Psychotic-like Symptoms
Interventions: Ketamine, TAK-063, TAK-063 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Alzheimer Disease
Interventions: Family-centered Function-focused Care (Fam-FFC); Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 65 Years and older
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 3
States / cities: Lancaster, Pennsylvania • Philadelphia, Pennsylvania • West Chester, Pennsylvania

Conditions: Healthy
Interventions: Placebo, PF-06818883; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Influenza
Interventions: CR8020, CR6261, Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 21
States / cities: Fresno, California • Stanford, California • Washington D.C., District of Columbia + 18 more

Conditions: Drug Abuse
Interventions: Intravenous placebo, Intranasal placebo, Intravenous racemic ketamine, Esketamine 112 mg, Esketamine 84 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pneumococcal Infection
Interventions: V110, V114, mRNA-1273, Placebo for V110, Placebo for V114; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years and older
Enrollment: 850 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 42
States / cities: North Hollywood, California • Northridge, California • Paramount, California + 38 more

Conditions: Healthy
Interventions: Selpercatinib, Moxifloxacin, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Alcohol Drinking, Alcohol Intoxication, Alcohol Use, Unspecified
Interventions: WayToServe Plus In-service Component, WayToServe Training Only; Behavioral
Lead sponsor: Klein Buendel, Inc.; Industry
Eligibility: 19 Years and older
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Golden, Colorado

Conditions: Healthy Subjects
Interventions: 0.5 mg/kg Lpathomab, 1.0 mg/kg Lpathomab, 3.0 mg/kg Lpathomab, 10 mg/kg Lpathomab, 20 mg/kg Lpathomab, Saline solution for intravenous infusion; Biological · Other
Lead sponsor: Lpath, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Diabetes Mellitus, Type 2
Interventions: JNJ 28431754, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Chula Vista, California

Search by objective public record fields.

A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip Application

Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

A Within Subjects Comparison of Two Antegrade Flushing Regimens in Children

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)

Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

Robotic Exoskeleton Assisted Gait Post Stroke

Medication Empowerment and Deprescription for Safety (MEDS) Study

Spatiotemporal tSCS in Spinal Cord Injury

Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote

Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06

PREVENT Pilot HPV - Related Cancers Trial

A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults

A Family-centered Intervention for Acutely-ill Persons With Dementia

Safety and Tolerability of PF-06818883 in Healthy Subjects

Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection

Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants

WayToServePlus: Improving Responsible Alcohol Service Ph II

A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus